Over $500K Ionis (NASDAQ: IONS) stock sale planned under Rule 144

Rhea-AI Filing Summary

Ionis Pharmaceuticals insider plans a Rule 144 stock sale. A holder intends to sell 6,179 shares of Ionis common stock through Morgan Stanley Smith Barney on or about 01/30/2026 on NASDAQ, with an aggregate market value of $512,905.75.

The shares were acquired on 01/29/2026 as performance stock units granted under Ionis’ 2011 Equity Incentive Plan and paid as compensation. The filer also reports a prior sale in the last three months of 9,191 common shares for gross proceeds of $697,045.44.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney 1585 Broadway New York NY 10036	6179	512905.75	161137930	01/30/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/29/2026	PSUs granted under 2011 Equity Incentive Plan	Ionis Pharmaceuticals			6179	01/29/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Morgan Stanley Smith Barney 1585 Broadway New York CA 10036	Common Stock	01/16/2026	9191	697045.44

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for Ionis Pharmaceuticals (IONS) disclose?

The filing discloses that an Ionis Pharmaceuticals shareholder intends to sell 6,179 shares of common stock under Rule 144. The sale is planned through Morgan Stanley Smith Barney on or about January 30, 2026, on NASDAQ, with an aggregate market value of $512,905.75.

How many Ionis Pharmaceuticals (IONS) shares are being sold and at what value?

The filer plans to sell 6,179 Ionis Pharmaceuticals common shares with an aggregate market value of $512,905.75. This planned transaction is disclosed under Rule 144, indicating a proposed public resale of restricted or control securities through a broker on NASDAQ.

How were the Ionis Pharmaceuticals (IONS) shares in this Form 144 acquired?

The 6,179 Ionis Pharmaceuticals shares were acquired on January 29, 2026, as performance stock units granted under the company’s 2011 Equity Incentive Plan. They were received as compensation rather than purchased for cash, and are now being registered for resale under Rule 144.

Which broker will handle the planned Ionis Pharmaceuticals (IONS) share sale?

Morgan Stanley Smith Barney, located at 1585 Broadway, New York, NY 10036, will handle the planned sale of 6,179 Ionis Pharmaceuticals common shares. The filing lists NASDAQ as the securities exchange where the transaction is expected to occur around January 30, 2026.

Were there recent Ionis Pharmaceuticals (IONS) stock sales by the same seller?

Yes. The filing reports a prior sale during the past three months by the same account: 9,191 Ionis Pharmaceuticals common shares sold on January 16, 2026, generating gross proceeds of $697,045.44. This historical activity is disclosed as part of the Rule 144 requirements.

What is the total number of Ionis Pharmaceuticals (IONS) shares outstanding mentioned?

The document states that 161,137,930 Ionis Pharmaceuticals common shares are outstanding. This figure provides context for the planned 6,179-share Rule 144 sale, showing the size of the proposed transaction relative to the company’s total common stock base.